Clinical Trial Update: NVA237 BID Versus Placebo Twelve-week Efficacy Study [Phase 3]

View source ↗

Summary

This Phase 3 twelve-week efficacy study compared NVA237 (umeclidinium) twice daily to placebo in chronic obstructive pulmonary disease. Results of the trial wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-03-11